Day: May 31, 2024

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication. The FDA had requested additional analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials. Based on the submission of these analyses earlier in May, the agency has now determined that this additional information...

The net asset value (NAV) of EfTEN United Property Fund unit was 10.70 euros at the end of April, increasing by 0.9% over the month. The jump in NAV was related to the investment of the listed fund EfTEN Real Estate Fund AS, whose shares closed on the Tallinn stock exchange at 4% higher than a month ago. The fund’s return on unlisted investments was on average 0,4% in April. In May, EfTEN United Property Fund invested 255 thousand euros in the EfTEN Residential Fund, which was used to complete the construction of a rental house with 145 apartments in Vilnius. This was the fund’s last investment in the rental apartments segment. The completion of the Vilnius rental house is planned for the coming summer, after which the building will start generating cash flow for the fund. In the Uus-Järveküla residential development May was...

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent® (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils....

Dupixent recommended for EU approval by the CHMP to treat patients with COPDRecommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decadeParis and Tarrytown, N.Y. May 31, 2024. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The European Commission...

Please find attached the 2024 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.Attachment2024 Salmon Industry Handbook

Renault Group and Geely announce the creation of leading Powertrain Technology Company, “HORSE Powertrain Limited”Following the agreements signed on July 11, 2023 by Renault Group and Geely, and after having obtained the approval of the relevant authorities, HORSE Powertrain Limited has been officially created on May 31, 2024 with each group holding 50% stake in the new company. The new company will lead the market for hybrid and combustion powertrain components and systems. Matias Giannini is appointed CEO of HORSE Powertrain limited. The Board of directors of HORSE Powertrain Limited will be chaired by Daniel Li and will have 6 directors with equal representation from its shareholders. HORSE Powertrain Limited expects to reach c. €15 billion in annual revenues and a production of c. 5 million powertrain units per year and will have...